A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Here are four things to know. 1. Biktarvy is a once-daily, triple-combination tablet used to treat HIV infections. 2. The drug’s wholesale price will be about $36,000 per year, which falls in line ...

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

A few weeks ago, Grant Ogren and Rhea Ashby-Durall, the executive director and the outreach manager of SAN (formerly Spokane AIDS Network), met with their representative from Gilead Sciences, the ...

According to UNAIDS, in 2024, about 40.8 million people around the world were living with the human immunodeficiency virus (HIV) — a virus that can lead to acquired immunodeficiency syndrome (AIDS) if ...

The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...

Modern-day HIV treatments may stem from a genetic mutation dating back to the Viking Age, researchers said. Steinar Engeland via Unsplash On June 5, 1981, the Centers for Disease Control and ...